International external quality assurance of JAK2 V617F quantification.
External quality assurance
JAK2 V617F
Myeloproliferative neoplasms
Quantitative PCR
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
11
11
2018
accepted:
26
11
2018
pubmed:
12
12
2018
medline:
26
4
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
External quality assurance (EQA) programs are vital to ensure high quality and standardized results in molecular diagnostics. It is important that EQA for quantitative analysis takes into account the variation in methodology. Results cannot be expected to be more accurate than limits of the technology used, and it is essential to recognize factors causing substantial outlier results. The present study aimed to identify parameters of specific importance for JAK2 V617F quantification by quantitative PCR, using different starting materials, assays, and technical platforms. Sixteen samples were issued to participating laboratories in two EQA rounds. In the first round, 19 laboratories from 11 European countries analyzing JAK2 V617F as part of their routine diagnostics returned results from in-house assays. In the second round, 25 laboratories from 17 countries participated. Despite variations in starting material, assay set-up and instrumentation the laboratories were generally well aligned in the EQA program. However, EQA based on a single technology appears to be a valuable tool to achieve standardization of the quantification of JAK2 V617F allelic burden.
Identifiants
pubmed: 30535576
doi: 10.1007/s00277-018-3570-8
pii: 10.1007/s00277-018-3570-8
pmc: PMC6469832
doi:
Substances chimiques
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1111-1118Subventions
Organisme : Austrian Science Fund
ID : F4702-B20 and P29018-B30
Références
N Engl J Med. 2003 Oct 9;349(15):1423-32
pubmed: 14534335
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187
Clin Chem Lab Med. 2005;43(5):542-8
pubmed: 15899677
Blood. 2006 May 1;107(9):3676-82
pubmed: 16373657
Blood. 2006 Jul 1;108(1):28-37
pubmed: 16522812
Blood. 2006 Sep 15;108(6):1865-7
pubmed: 16728702
Leukemia. 2007 May;21(5):1128-30
pubmed: 17301814
Br J Haematol. 2007 Mar;136(5):745-51
pubmed: 17313377
Blood. 2008 Oct 15;112(8):3065-72
pubmed: 18650451
Haematologica. 2009 Jan;94(1):38-45
pubmed: 19001280
Blood. 2010 Nov 25;116(22):e111-7
pubmed: 20720184
Br J Haematol. 2013 Jan;160(1):25-34
pubmed: 23057517
Leukemia. 2013 Oct;27(10):2032-9
pubmed: 23860450
Leukemia. 2015 Feb;29(2):369-76
pubmed: 25036192
Leuk Lymphoma. 2016 Feb;57(2):348-354
pubmed: 25956046
Oncotarget. 2017 May 16;8(20):32608-32617
pubmed: 28427233